Sonigra Khushboo J, Sarna Krishan, Vaghela Vinesh P, Guthua Symon
Department of Oral and Maxillofacial Surgery, Oral Pathology and Oral Medicine, University of Nairobi, Nairobi, KEN.
Department of Internal Medicine, Coast General Teaching and Referral Hospital, Mombasa, KEN.
Cureus. 2022 Mar 17;14(3):e23251. doi: 10.7759/cureus.23251. eCollection 2022 Mar.
A myasthenic crisis is a severe, life-threatening exacerbation of myasthenia gravis that causes a rapid onset of muscle weakness and fatigue that may result in tetraparesis, dyspnea, respiratory insufficiency, aspiration, and death. Bulbar muscle functions are markedly affected resulting in depressed cough reflex, swallowing, and speech. Thus, mechanical ventilation, supportive feeding, and critical care are essential for the survival of patients in a myasthenic crisis. Numerous precipitating factors of this condition are well known and include infections, various medications, pregnancy, and childbirth. Patients with myasthenia gravis are at a considerably higher risk of developing a debilitating coronavirus disease 2019 (COVID-19) infection due to the associated immunosuppression resulting from long-term corticosteroid use, which makes vaccination of such individuals necessary. However, the relationship between an exacerbation of myasthenia gravis and the COVID-19 vaccination is currently unknown. In this paper, we report the case of a 55-year-old male patient who developed a myasthenic crisis after receiving the first dose of the ChAdOx1-S (recombinant) vaccine (AstraZeneca batch number 210157; AstraZeneca plc, Cambridge, United Kingdom). Despite the administration of aggressive and intensive treatment over a period of 29-day hospitalization, the myasthenic crisis could not be reversed and the patient ultimately deteriorated and succumbed from multiple myocardial infarction events and organ failures. While it is still uncommon, evidence associating the effects of the vaccine to the development of a crisis is mounting; therefore, it is crucial for clinicians to promptly identify clinical features that suggest an exacerbation of myasthenia gravis in order to intervene at the earliest possible stage for a more favorable outcome. The myasthenia gravis patient should be informed about the possible association between COVID-19 vaccination and the development of a myasthenic crisis.
重症肌无力危象是重症肌无力严重的、危及生命的加重状态,会迅速出现肌肉无力和疲劳,可能导致四肢轻瘫、呼吸困难、呼吸功能不全、误吸及死亡。延髓肌功能受到显著影响,导致咳嗽反射、吞咽及言语功能减弱。因此,机械通气、支持性喂养及重症监护对于重症肌无力危象患者的存活至关重要。该病症有许多已知的诱发因素,包括感染、各种药物、妊娠及分娩。由于长期使用皮质类固醇导致相关免疫抑制,重症肌无力患者感染严重急性呼吸综合征冠状病毒2型(COVID-19)的风险显著更高,这使得此类患者有必要接种疫苗。然而,目前尚不清楚重症肌无力加重与COVID-19疫苗接种之间的关系。在本文中,我们报告了一例55岁男性患者的病例,该患者在接种第一剂ChAdOx1-S(重组)疫苗(阿斯利康批号210157;阿斯利康公司,英国剑桥)后发生了重症肌无力危象。尽管在为期29天的住院期间进行了积极强化治疗,但重症肌无力危象无法逆转,患者最终病情恶化,死于多次心肌梗死事件和器官衰竭。虽然这种情况仍然不常见,但将疫苗作用与危象发生相关联的证据越来越多;因此,临床医生及时识别提示重症肌无力加重的临床特征至关重要,以便尽早干预以获得更有利的结果。应告知重症肌无力患者COVID-19疫苗接种与重症肌无力危象发生之间可能存在的关联。